HIND · XBRL financial data

Vyome Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (HIND's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	—	—	—	85	61*	199	50	35	37*	32	27
Revenue from contracts with customers	2,155	1,982*	1,944	1,965	2,292	1,805*	1,113	1,242	—	—	—	—
Cost of goods and services sold	867	140*	779	831	853	486*	432	643	17	14*	15	15
Gross profit	1,288	—	1,165	1,134	1,439	—	681	599	18	—	17	12
Research and development	542	739*	484	399	399	521*	364	476	40	378*	666	507
Selling, general and administrative	1,791	1,398*	1,019	670	719	(1,509)*	260	265	844	996*	478	365
General and administrative	2,058	1,600*	1,872	2,119	2,082	857*	1,627	1,591	—	—	—	—
Total operating expenses	5,168	3,737*	3,375	3,188	3,200	3,021*	2,887	3,361	8,592	1,377*	1,147	874
Operating income (loss)	(3,880)	(1,895)*	(2,210)	(2,054)	(1,761)	(1,702)*	(2,206)	(2,762)	(8,574)	(1,355)*	(1,130)	(863)
Interest expense	—	—	—	—	46	53*	55	56	26	10*	3	3
Other income (expense)	0*	114*	25	59	109	0*	54	60	5	85*	147	146
Income tax expense (benefit)	3	31*	14	15	6	5*	7	8	—	—	—	—
Net income (loss)	(3,534)	(1,698)*	(2,193)	(1,595)	(1,581)	(1,761)*	1,474	(2,630)	(8,434)	(1,225)*	(963)	(686)
Earnings per share, basic‡ USD per share	(87,209.30)	—	(7,694.94)	(5,129.96)	(4,520.35)	—	474.50	(2.25)	(3.12)	—	(0.15)	(0.10)
Earnings per share, diluted‡ USD per share	(87,209.30)	—	(7,694.94)	(5,129.96)	(4,520.35)	—	474.50	(2.25)	(3.12)	—	(0.15)	(0.10)
Weighted average shares, basic‡ thousands of shares	0	—	0	0	0	—	3	1,169	2,758	—	6,690	7,019
Weighted average shares, diluted‡ thousands of shares	0	—	0	0	0	—	3	1,169	2,758	—	6,690	—

‡ Per-share figures and share counts are adjusted for the 1-for-58.8235294117647 stock split (September 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-58.13953488372093 stock split (September 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (May 2025); filings made before it reported them unadjusted.
† Share count changed about 921x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/15 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 91x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (HIND's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,449	4,459	2,379	1,053	743	693	2,515	4,123	5,707	4,982	8,796	7,888
Accounts receivable	—	1,700	1,600	1,400	1,300	1,000	700	1,400	23	0	0	2
Inventory	3,204	3,741	3,467	3,246	2,934	2,460	2,532	2,552	—	—	—	—
Prepaid and other current assets	493	337	383	306	217	348	414	707	—	456	367	266
Total current assets	7,399	10,296	7,895	6,087	5,338	4,588	6,295	8,862	6,037	5,438	9,163	8,153
Property and equipment, net	70	60	54	48	43	38	34	30	50	46	44	42
Right-of-use asset	274	250	226	202	177	116	99	79	37	29	21	15
Total assets	7,827	10,663	8,231	6,393	5,615	4,793	6,483	9,028	7,045	6,497	10,185	9,176
Accounts payable	1,462	1,689	1,314	1,030	2,105	2,208	1,686	1,346	1,654	648	532	547
Accrued liabilities	2,734	1,814	1,930	1,895	1,643	1,688	2,158	1,586	249	639	590	517
Total current liabilities	4,469	3,777	3,519	3,201	4,025	4,985	4,123	3,199	3,119	2,735	2,144	1,865
Lease liability, non-current	175	151	127	103	77	41	14	—	8	—	—	—
Total liabilities	4,744	4,000	3,697	3,358	4,128	5,046	5,253	3,199	3,127	2,735	2,144	1,865
Accumulated deficit	(633,876)	(635,574)	(637,767)	(639,362)	(640,943)	(642,704)	(641,230)	(643,860)	(86,338)	(87,564)	(88,526)	(89,212)
Total stockholders' equity	3,083	6,663	4,534	3,035	1,487	(253)	1,230	5,829	2,530	—	—	—
Total liabilities and equity	7,827	10,663	8,231	6,393	5,615	4,793	6,483	9,028	7,045	6,497	10,185	9,176
Common shares outstanding (cover page)‡ thousands of shares	0	0	0	0	0	451	30	2,693	5,644	7,019	7,019	7,019

‡ Per-share figures and share counts are adjusted for the 1-for-58.8235294117647 stock split (September 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-58.13953488372093 stock split (September 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (May 2025); filings made before it reported them unadjusted.
† Share count changed about 921x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/15 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 91x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (HIND's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(3,534)	(1,698)*	(2,193)	(1,595)	(1,581)	(1,761)*	1,474	(2,630)	(8,434)	(1,225)*	(963)	(686)
Stock-based compensation	216*	110*	72	65*	32*	15*	15	12*	547*	3*	6	11*
Net cash from operating activities	(2,780)*	(2,457)*	(2,072)	(1,357)*	(311)*	(687)*	(2,119)	(4,494)*	4,342*	(1,478)*	(1,436)	(904)*
Net cash from investing activities	0*	0*	—	—	—	1*	—	—	—	—	—	—
Proceeds from issuing common stock	0*	987*	10,200	0*	—	—	4,758	6,101*	(10,179)*	603*	5,289	(3)*
Net cash from financing activities	(338)*	5,461*	—	—	0*	653*	3,947	6,101*	(2,157)*	764*	5,289	(3)*
Net change in cash	(3,118)*	3,010*	(2,080)	(1,326)*	(310)*	(50)*	1,822	1,608*	2,175*	(725)*	3,813	(908)*

† Share count changed about 921x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/15 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 91x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
AIM ImmunoTech	9,900	26	(4,590)*	30.4M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Adial Pharmaceuticals	28,712	not reported	(6,363)*	2.6M	4.5 quarters	Q2 FY26 10-Q/AJun 30, 2026
PharmaCyte Biotech	17,739	0	(781)	10.7M	22.8 quarters	Q1 FY27 10-QJul 31, 2026
Natural Alternatives International	7,388	not reported	(1,066)*	22.1M	6.9 quarters	Q4 FY26 10-KJun 30, 2026
LFTD Partners	1,504	8,705	(555)*	14.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Biomerica	2,733	1,265	(802)	4.6M	3.4 quarters	Q1 FY27 10-QAug 31, 2026
America Great Health	29	26	1.7*	21.2B	—	Q3 FY26 10-QMar 31, 2026
Protagenic Therapeutics, Inc.\new	566	not reported	(944)	1.8M	0.6 quarters	Q1 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.